BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services, and others. It generates the majority of its revenue from the Pharmacy Solutions segment.
Last trade$69.64
Day change-$1.73 (-2.42%)
Day range$69.41 – $72.11
Volume819,649
Market cap$14.20B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$14.2B
Price / earnings
34.61×
Price / book
6.52×
Price / sales
0.93×
EV / sales
1.03×
EV / EBITDA
23.1×
Profitability
Earnings per share
$2.06
Return on assets
6.55%
Return on equity
18.85%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.01×
Current ratio
1.62×
Quick ratio
1.22×
Cash ratio
0.42×
Cash flow
Price / cash flow
23.56×
Price / free cash flow
28.84×
Free cash flow
$492.41M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BTSG, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$4.21B
$3.87B
$3.61B
$3.55B
$3.33B
$3.15B
$2.88B
$2.75B
Cost of revenue
$3.69B
$3.38B
$3.13B
$3.14B
$2.94B
$2.77B
$2.54B
$2.41B
Gross profit
$518.55M
$492.75M
$482.22M
$412.55M
$392.01M
$374.85M
$338.37M
$338.67M
Selling, general and administrative
$358.07M
$362.36M
$360.77M
$304.44M
$304.17M
$326.3M
$287.63M
$283.13M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$358.07M
$362.36M
$360.77M
$304.44M
$304.17M
$326.3M
$287.63M
$283.13M
Operating income
$160.48M
$130.39M
$121.45M
$108.11M
$87.84M
$48.56M
$50.74M
$55.54M
Interest expense
-$31.04M
-$36.88M
-$38.62M
-$38.54M
-$38.24M
-$38.78M
-$41.76M
-$46.18M
Income before taxes
$129.44M
$93.51M
$82.83M
$69.58M
$49.61M
$9.78M
$8.98M
$9.36M
Income taxes
$28.64M
$6.91M
$8.55M
$20.03M
$12.12M
$1.24M
-$240K
$5.08M
Net income
$100.3M
$84.21M
$148.61M
$77.32M
$55.24M
$27.54M
$29.01M
$15.4M
Net income attributable to common shareholders
$100.14M
$84.29M
$148.77M
$77.08M
$55.84M
$28.21M
$29.54M
$16M
EBITDA
$198.85M
$171.81M
$160.54M
$147.64M
$128.6M
$90.4M
$92.9M
$110.42M
Basic earnings per share
$0.48
$0.41
$0.73
$0.38
$0.27
$0.14
$0.15
$0.08
Diluted earnings per share
$0.45
$0.38
$0.67
$0.34
$0.26
$0.13
$0.14
$0.08
Recent news
Company coverage with links to the original publishers.
Medtronic is expected to report Q2 fiscal 2027 results on November 24, with revenues projected to grow 5.7% to $9.47 billion and EPS estimated at $1.34 (down 1.5% YoY). The Cardiovascular segment is expected to drive growth at 9.6%, supported by cardiac ablation, CRM, and structural heart products. Diabetes revenues are projected to grow 12.9% following the MiniMed separation. However, the company has a negative Earnings ESP of -0.75%, suggesting limited upside surprise potential.
Zacks equity research analysts identified five growth stocks with Zacks Rank #1 (Strong Buy) ratings and Growth Score of A for November investment: Quanta Services, BrightSpring Health Services, Phillips 66, Valero Energy, and HF Sinclair. These stocks are positioned to benefit from infrastructure spending, AI data center expansion, refining fundamentals, and renewable energy trends.
Zacks Investment Research identifies five growth stocks with Strong Buy ratings and A Growth Scores as attractive November purchases: Quanta Services (PWR), BrightSpring Health Services (BTSG), Phillips 66 (PSX), Valero Energy (VLO), and HF Sinclair (DINO). These stocks benefit from infrastructure demand, healthcare expansion, refining strength, and renewable energy initiatives, with expected earnings growth ranging from 62.7% to over 100% for the current year.
In a comparison of two Medical Services sector stocks, BrightSpring Health Services (BTSG) emerges as the better value investment option compared to Caris Life Sciences (CAI). BTSG holds a Zacks Rank of #1 (Strong Buy) with a forward P/E of 35.08 and Value grade of B, while CAI has a Zacks Rank of #3 (Hold) with a forward P/E of 234.70 and Value grade of D. BTSG's superior earnings estimate revisions and more attractive valuation metrics make it the preferred choice for value investors.
BrightSpring Health Services (BTSG) is highlighted as an attractive investment opportunity combining momentum with value. The stock has gained 5.4% over four weeks and 8.8% over 12 weeks, with a beta of 1.77 indicating high volatility. Despite strong momentum, BTSG trades at a reasonable valuation with a Price-to-Sales ratio of 0.88x, earning a Zacks Rank #1 (Strong Buy) rating based on upward earnings estimate revisions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.